Simplify Logo

Full-Time

Senior Medical Director

Clinical Development

Posted on 6/27/2024

Axsome Therapeutics Inc

Axsome Therapeutics Inc

501-1,000 employees

Develops therapies for CNS disorders

Biotechnology
Healthcare

Compensation Overview

$260k - $280kAnnually

+ Bonus + Equity

Senior, Expert

New York, NY, USA

Requires onsite presence in New York City for at least three days per week.

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Requirements
  • MD or foreign equivalent specializing in neurology or with significant development experience in CNS; PharmD will be considered commensurate with extensive drug development experience with CNS/neurology
  • Postgraduate training with at least 5 years of drug safety, clinical development, or medical affairs experience in the pharmaceutical industry
  • Understanding of pharmacovigilance regulatory environment with working knowledge of international regulations, initiatives, standards, Good Pharmacovigilance Practices (GVP), and Good Clinical Practice (GCP), Council for International Organizations of Medical Sciences (CIOMS), ICH guidelines, regulatory authority regulations/guidelines, and applicable SOPs
  • Ability to work on site Monday, Tuesday & Thursday
Responsibilities
  • Independently generate and review clinical trial protocols/concept sheets and investigator brochures (IBs) and collaborate directly with Key Opinion Leaders for expert feedback for assigned assets and projects
  • Provide therapeutic area training
  • Act as a resource for the generation of informed consent forms, and review these forms for completeness in risk assessment as compared to clinical trial protocols and investigator brochures
  • Provide safety training for clinical sites and internal team members
  • Engage with clinical team to answer eligibility and other medical related questions associated with clinical trials (e.g., abnormal laboratory test result review)
  • Author or support the authorship of all required medical plans (e.g., Safety Monitoring Plan, Medical Monitoring Plan) for each clinical trial
  • Participate in the clinical trial risk assessment
  • Review medical coding of clinical trial data, throughout the lifecycle of a clinical trial
  • Review protocol deviations to identify safety trends that could requirement modification of the protocol
  • Provide medical expertise in the assessment of ICSRs and aggregate drug safety reports
  • Review and oversight of serious adverse events, including review of case narratives
  • Provide medical interpretation of clinical safety data and determine the medical significance of any findings
  • Contribute to oversight of external safety vendor and provide medical input as needed
  • Contribute to the generation of aggregate safety reports including annual IND safety reports and periodic benefit risk evaluation reports
  • Review, analyze, and assess clinical trial safety data, and present the results as needed
  • Consult with external safety vendor and internal PV Operations as needed
  • Collaborate with relevant members of the study team, and vendor clinical staff who provide medical monitoring support for ongoing clinical trials
  • Lead medical input for scientific publications (e.g., abstracts, posters, papers) for scientific meetings and journals
  • Collaborate with Regulatory Affairs to ensure appropriate reporting of pharmacovigilance and drug safety information to regulatory agencies and prescriber community
  • Contribute to regulatory submissions including authoring relevant sections of the submissions
  • Contribute to the development of internal processes including SOPs, guidelines, and Work Instructions
Axsome Therapeutics Inc

Axsome Therapeutics Inc

View

Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, and Alzheimer's agitation. Their main product, AXS-05, is an oral medication that works by blocking NMDA receptors in the brain to help regulate mood. This drug has shown positive results in clinical trials and has received FDA Breakthrough Therapy Designation, which speeds up its development process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and clinical trials. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.

Company Stage

IPO

Total Funding

$430.7M

Headquarters

New York City, New York

Founded

2012

Growth & Insights
Headcount

6 month growth

14%

1 year growth

14%

2 year growth

14%
Simplify Jobs

Simplify's Take

What believers are saying

  • The launch of Auvelity and the promising results of AXS-12 in Phase 3 trials indicate strong potential for revenue growth and market impact.
  • Axsome's strategic expansion of its sales force to support Auvelity's launch demonstrates its commitment to commercial success.
  • The appointment of experienced leaders like Dr. Sue Mahony to the board enhances Axsome's strategic direction and governance.

What critics are saying

  • The biopharmaceutical sector's inherent risks, including regulatory hurdles and clinical trial failures, could impact Axsome's progress.
  • High competition in the CNS disorder treatment market may challenge Axsome's ability to capture significant market share.

What makes Axsome Therapeutics Inc unique

  • Axsome Therapeutics focuses on CNS disorders with a strong emphasis on unmet medical needs, setting it apart from broader biopharmaceutical companies.
  • The FDA Breakthrough Therapy Designation for AXS-05 highlights its innovative approach and potential for rapid market entry.
  • Axsome's diversified pipeline, including treatments for MDD, TRD, Alzheimer's agitation, and narcolepsy, showcases its comprehensive strategy in CNS therapeutics.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE